KFP
GSK icon

Keystone Financial Planning’s GSK GSK Stock Holding History

Keystone Financial Planning’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3M Buy
195,590
+189,506
+3,115% +$10M 2.64% 5
2026
Q1 		$336K Buy
6,084
+1,432
+31% +$77.6K 0.09% 36
2025
Q4 		$228K Sell
4,652
-222,804
-98% -$10.4M 0.07% 43
2025
Q3 		$9.82M Sell
227,456
-1,659
-0.7% -$64.8K 2.85% 6
2025
Q2 		$8.8M Buy
229,115
+222
+0.1% +$8.48K 2.66% 5
2025
Q1 		$8.87M Buy
228,893
+980
+0.4% +$35.9K 2.64% 7
2024
Q4 		$7.71M Buy
227,913
+221,853
+3,661% +$7.99M 2.39% 9
2024
Q3 		$248K Buy
+6,060
New +$248K 0.08% 46
2024
Q2 		– Sell
-38,378
Closed -$1.65M – 51
2024
Q1 		$1.65M Sell
38,378
-7,848
-17% -$324K 0.53% 32
2023
Q4 		$1.71M Sell
46,226
-2,931
-6% -$105K 0.57% 32
2023
Q3 		$1.78M Sell
49,157
-614
-1% -$21.8K 0.62% 32
2023
Q2 		$1.77M Sell
49,771
-213,211
-81% -$7.65M 0.59% 33
2023
Q1 		$9.36M Sell
262,982
-1,098
-0.4% -$38.4K 3.18% 2
2022
Q4 		$9.28M Buy
264,080
+1,210
+0.5% +$40.3K 3.13% 3
2022
Q3 		$7.74M Buy
262,870
+74,344
+39% +$2.82M 2.97% 5
2022
Q2 		$10.3M Buy
188,526
+1,396
+0.7% +$77.1K 3.6% 3
2022
Q1 		$10.2M Buy
187,130
+447
+0.2% +$24.3K 3.41% 3
2021
Q4 		$10.3M Sell
186,683
-3,470
-2% -$181K 3.51% 2
2021
Q3 		$9.08M Buy
190,153
+6,895
+4% +$346K 3.3% 6
2021
Q2 		$9.12M Buy
183,258
+3,615
+2% +$174K 3.3% 7
2021
Q1 		$8.01M Buy
179,643
+5,724
+3% +$260K 2.99% 12
2020
Q4 		$8M Buy
173,919
+18,817
+12% +$864K 3.32% 9
2020
Q3 		$7.3M Buy
155,102
+8,673
+6% +$435K 3.53% 8
2020
Q2 		$7.47M Buy
146,429
+6,003
+4% +$308K 3.68% 7
2020
Q1 		$6.65M Buy
140,426
+11,747
+9% +$627K 3.81% 5
2019
Q4 		$7.56M Buy
128,679
+1,020
+0.8% +$56.7K 3.37% 10
2019
Q3 		$6.81M Buy
127,659
+2,085
+2% +$107K 3.25% 13
2019
Q2 		$6.28M Buy
125,574
+784
+0.6% +$39.3K 3.07% 13
2019
Q1 		$6.52M Buy
124,790
+18,438
+17% +$921K 3.22% 14
2018
Q4 		$5.08M Buy
106,352
+663
+0.6% +$32.7K 2.84% 16
2018
Q3 		$5.31M Buy
105,689
+1,028
+1% +$52.2K 2.71% 21
2018
Q2 		$5.27M Buy
104,661
+245
+0.2% +$12.3K 2.9% 19
2018
Q1 		$5.1M Buy
104,416
+1,134
+1% +$52.8K 2.84% 18
2017
Q4 		$4.58M Sell
103,282
-3,291
-3% -$152K 2.44% 20
2017
Q3 		$5.41M Buy
106,573
+1,768
+2% +$89.7K 3.07% 15
2017
Q2 		$5.65M Buy
104,805
+1,211
+1% +$64.6K 3.42% 11
2017
Q1 		$5.46M Buy
103,594
+7,030
+7% +$357K 3.39% 10
2016
Q4 		$4.65M Hold
96,564
– – 3.04% 15
2016
Q3 		$5.21M Buy
96,564
+782
+0.8% +$42.9K 3.42% 10
2016
Q2 		$5.19M Buy
95,782
+1,572
+2% +$82.8K 3.51% 12
2016
Q1 		$4.78M Buy
94,210
+142
+0.2% +$7.07K 3.42% 12
2015
Q4 		$4.75M Buy
94,068
+98
+0.1% +$5K 3.59% 11
2015
Q3 		$4.52M Buy
93,970
+2,781
+3% +$145K 3.65% 12
2015
Q2 		$4.75M Buy
91,189
+2,975
+3% +$168K 3.63% 10
2015
Q1 		$5.09M Buy
88,214
+28,924
+49% +$1.66M 3.87% 6
2014
Q4 		$3.17M Sell
59,290
-180
-0.3% -$10.1K 2.34% 24
2014
Q3 		$3.42M Buy
59,470
+26
+0% +$1.59K 2.58% 23
2014
Q2 		$3.97M Sell
59,444
-491
-0.8% -$33.2K 2.99% 19
2014
Q1 		$4M Buy
59,935
+277
+0.5% +$18.7K 3.1% 19
2013
Q4 		$3.98M Buy
+59,658
New +$3.87M 3.18% 15

Other funds holding GSK

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
BB
Bell Bank Fargo, North Dakota $2.62B AUM 23.93% 1-Year Est. Return
KIC
Keating Investment Counselors Delray Beach, Florida $364M AUM 22.11% 1-Year Est. Return
GHAM
Gilman Hill Asset Management New Canaan, Connecticut $731M AUM 19.41% 1-Year Est. Return
AWAG
ARS Wealth Advisors Group St. Petersburg, Florida $1.28B AUM 24.51% 1-Year Est. Return
HAI
Hennessy Advisors Inc Novato, California $3.13B AUM 77.26% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Keystone Financial Planning's GSK Position: Q2 2026 in Review

Keystone Financial Planning increased its GSK (GSK) stake by 3,115% in Q2 2026, buying an estimated $10M and bringing the position to 195,590 shares worth $10.3M. The position accounts for 2.64% of the portfolio, ranked #5.

Keystone Financial Planning first reported a position in GSK in Q4 2013 and has held it in 50 quarters since. The position peaked at $10.3M in Q4 2021. 161 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Keystone Financial Planning held 195,590 shares of GSK worth $10.3M as of Q2 2026.
  • Keystone Financial Planning bought 189,506 GSK shares in Q2 2026, an estimated $10M.
  • GSK made up 2.64% of Keystone Financial Planning's portfolio in Q2 2026, its #5 holding.
  • Keystone Financial Planning first reported a position in GSK in Q4 2013 and has held it in 50 quarters since.
  • Keystone Financial Planning's GSK position peaked at $10.3M in Q4 2021.
  • 161 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Keystone Financial Planning's 13F filing for Q2 2026, filed 15 Jul 2026.